Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I bought some too
This from the HEMP side yesterday
4:29 PM ET 6/7/17 | Dow Jones
HEMPCO FOOD AND FIBER INC. CORPORATE DEVELOPMENTS
Symbol: TSX.V -- HEMP
VANCOUVER, June 7, 2017 /CNW/ - Hempco Food and Fiber Inc. (TSX.V: HEMP) ("Hempco(R)") is pleased to announce a non-brokered private placement (the "Offering") of up to 11,382,113 units at $0.3075 per unit, each unit consisting of one common share of Hempco and one warrant to purchase one common share of Hempco (a "Warrant"). Each Warrant shall be valid for 2 years and shall be exercisable at a purchase price of $0.41 per warrant. Closing of the Offering is subject to a number of conditions, such as approval from the TSXV and satisfactory due diligence by the subscriber.
The private placement is subject to TSX Venture Exchange approval. The proceeds will be used for working capital purposes: new hires, marketing, equipment purchase and installation, quality control and software systems implementation.
All securities issued under the private placement are subject to a four month and one day hold period.
We seek Safe Harbor.
ON BEHALF OF THE BOARD
"Charles Holmes"
Charles Holmes
Chief Executive Officer
HEMPCO FOOD AND FIBER INC.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements in this press release regarding the Company which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Such information can generally be identified by the use of forwarding-looking wording such as "may", "expect", "estimate", "anticipate", "intend", "believe" and "continue" or the negative thereof or similar variations. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties such as the risk that the closing may not occur for any reason. Actual results in each case could differ materially from those currently anticipated in such statements due to factors such as the decision of the TSXV to reject any grant of options or any person to act as investor relation service providers. Except as required by law, the Company does not intend to update any changes to such statements.
SOURCE Hempco Food and Fiber Inc.
Good Morning...We have news!!!
Aurora to Make Strategic Investment in Hempco
Google+
Share with LinkedIn
Agreement Includes Option to Acquire up to 50.1% of Hempco on Fully Diluted Basis
TSXV: ACB TSXV: HEMP
VANCOUVER and BURNABY, BC, June 8, 2017 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Hempco Food and Fiber Inc. ("Hempco") (TSX-V: HEMP) are pleased to announce that Aurora will be making a strategic investment in Hempco for an ownership stake of up to 19.9% on a fully diluted basis, subject to Regulatory and Board approvals, as well as satisfactory completion of due diligence. Additionally, subject to customary conditions, Aurora will obtain an option to acquire shares from the majority owners of Hempco that, upon exercise of the option, will bring Aurora's total ownership interest in Hempco to 50.1% on a fully diluted basis.
Hempco is one of the world's largest industrial producers of hemp and hemp products, and currently offers three primary product lines: (1) bulk and packaged food products (e.g. hemp protein powder, hemp seeds or hearts, hemp oil etc.); (2) hemp fibre; and (3) nutraceuticals. Hempco's line of packaged foods are sold under the brand "Planet Hemp" and are distributed globally in seven countries.
The target market for these products includes, but is not limited to, health conscious consumers, including vegetarians seeking to supplement protein and reduce or eliminate animal product intake, as well as an increasing number of consumers focused on managing and preventing a variety of health issues through a healthy diet, known as "LOHAS", Lifestyles of Health and Sustainability, and "millenials" looking for clean and "green" products.
Hempco, a rapidly growing company
For the six month period ending February 28, 2017, Hempco recorded revenues of approximately $4.5 million, a 136% increase over the comparable period in the prior year.
In order to meet growing global demand for its hemp-based products, Hempco currently is completing the construction of a facility in Leduc County, less than 5 km from the Aurora Sky production facility now under construction at Edmonton International Airport. Upon completion, Hempco's new facility will double its current capacity to a total of approximately 225,000 kg per month of hulled hemp seed. Additionally, the Alberta facility is easily scalable and can be expanded to approximately 600,000 kg per month.
Strategic rationale
Industrial hemp grown under contract to Hempco contains efficient extractable quantities of cannabidiol, (CBD) a compound shown through a growing body of anecdotal and scientific evidence to have considerable medical benefits in symptom management.
Aurora anticipates, based on recommendation by the Federal Task Force on Cannabis Legalization, that the regulations preventing industrial hemp producers from harvesting leaves, flowers and buds, which contain CBDs will be revised to allow for the processing of CBDs. Cannabidiol does not have any intoxicating effects such as those caused by tetrahydrocannabinol (THC).
The market for CBDs in the form of capsules, oils, and topicals is expected to show significant growth, and Aurora considers the proposed transaction with Hempco to be a strategic initiative to enable market share dominance in this attractive segment.
Through its relationship with Radient Technologies Inc, (TSXV: RTI), the Company has access to an efficient, cost-effective, high-throughput methodology of producing CBD-based products at large scale, thus providing the Company with a considerable competitive advantage in addressing this growing market when CBD extraction from hemp is allowed.
Additionally, the FFNHP (Functional Foods and Natural Health Products) is a rapidly developing segment of the nutritional industry, with global demand for these products growing at a substantially higher rate than the traditional processed food market. Hempco's strong position within the hemp based nutrition space makes the company an attractive synergistic partner, irrespective of potential changes in legislation that would allow the harvest of CBD containing plant materials.
Management commentary
"Hempco is a rapidly expanding company with a strong and broadly diversified product offering, across a variety of health-related markets," said Terry Booth, CEO. "Leveraging our relationship with extraction leaders, the potential to develop a high-volume, low-cost source for CBD-based products creates significant upside potential, making this transaction particularly attractive. The proposed transaction would further strengthen the foundation on which we are building our high-margin concentrates business, as well as bring further diversification to our expanding product offering."
Charles Holmes, CEO of Hempco, added, "The transaction with Aurora provides us with the resources to accelerate our commercial development. Additionally, it provides us with a very highly visible partner, whose strong brand recognition we can leverage to grow our market share. The strategic location of both our new facilities by the Edmonton International Airport, and within close proximity of world class extraction processing facilities, provides further important logistical advantages as we expand our international reach. Hempco is delighted to be working with the world class Aurora team who share our vision and intentions to play a leading role in shaping the future of the global hemp industry."
The Investment
Aurora's investment in Hempco, subject to aforementioned conditions, will take place in two stages.
Aurora will loan Hempco $750,000 at an 8% interest rate. The loan is repayable upon the earliest of: June 8, 2019, a demand by Aurora for repayment, such demand which can only be made on or after December 21, 2017, or the completion of all or any portion of Hempco's non brokered private placement of units, as announced by Hempco on June 7, 2017, and:
Upon satisfactory completion of due diligence by Aurora as well as the satisfaction of a number of other conditions, Aurora as the sole investor, will participate in a private placement with Hempco to acquire a total of 10,558,676 units, priced at $0.3075 per unit, for total gross proceeds of $3.2 million. Upon completion of the private placement, Aurora shall hold 19.9% of the share capital in Hempco on a fully diluted basis. Each unit shall consist of one share and one full warrant. Each warrant gives Aurora the right to purchase, for a period of two years following the closing date, one common share of Hempco for a price of $0.41.
Additionally, as one of Aurora's conditions to participate in Hempco's private placement, Aurora will obtain a call option, agreed upon with the two majority owners of Hempco to purchase additional shares of Hempco from the majority owners, such that upon exercising the call option, Aurora will own 50.1% of the shares of Hempco.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport, and has acquired, and is undertaking completion of, a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal's West Island. Aurora also recently acquired Pedanios GmbH, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union ("EU"), based in Berlin, Germany. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the only Australian company licensed to conduct research on and cultivate medical cannabis, Aurora's common shares trade on the TSX-V under the symbol "ACB". Visit www.auroramj.com for more information.
About Hempco
For more than 15 years Hempco has been a trusted and respected pioneer, innovator and provider of premier hemp seed foods. Hempco is committed to developing hemp foods, hemp fiber and hemp nutraceuticals, a "tri-crop" opportunity for producers and processors. Hempco has grown its business significantly and is generating value and profits for shareholders.
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Companies are under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO
SOURCE Aurora Cannabis Inc.
For further information: Aurora Cannabis Inc.: Cam Battley, Executive Vice President, +1.905.864.5525, cam@auroramj.com; Marc Lakmaaker, NATIONAL Equicom, +1 416 848 1397, mlakmaaker@national.ca; Hempco Food and Fiber Inc.: Don Mosher, Business Development Executive, +1 604-685-6465, don@hempcocanada.com, www.hempcocanada.com
Organization Profile
Aurora Cannabis Inc.
Aurora and Radient Technologies Announce Positive Results from Research Joint Venture
Aurora Appoints Allan Cleiren as COO
Aurora Acquires German Medical Cannabis Market Leader Pedanios GmbH
More on this organization
As usual Thank You
Agreed
Most online charts have it going back up
E Trade the same
E-Trade still not showing Fridays News
Thank you for the pictures
Have my buy order in
Anyone else in UBQU? Dont let the name fool you!!
Some more positive analysis Here
TOP NEWS
INVESTING
ECONOMY
ENERGY
TECH
HEALTHCARE
WATCH LIST
Money News USA
Hot Stock UBQU Could Soar More Than 500%…
Ubiquitech Software Corp. (OTC: UBQU)
There is a new and dynamic sector within the Healthcare industry that is changing the game. Its medical benefits are proving to be astronomical and we may have potentially found a company that is poised to be at the forefront of this explosive new industry; a cutting-edge company that combines state-of-the-art technology with a reputable range of diverse medical products.
But first, let’s take a quick look at this sector as a whole:
The US Cannabis market size alone is forecasted to represent approximately $44 billion dollars, and according to a recent Washington Post article, it speculates that there’s up to $120 Billion unaccounted for in what some refer to as “the black market.“ Add in the nutritional supplement market of nearly $37 billion dollars and you have approximately a $200 billion dollar market opportunity.
Now back to this powerful play…
This is one of those rare stock market opportunities that is cashing in on this booming new industry. Through our exhaustive research, we have uncovered a true gem of a company, one with a combination of cheap valuation, catalysts, and explosive growth trends within this emerging sector.
This company has a valuable, growing customer base that all investors will soon want to own a part of. The stock price could TRIPLE or even QUADRUPLE in the short space of 3 months.
This company’s products are at the forefront of the market, merging the highest quality ingredients in the US with a savvy and successful marketing strategy. We decided to feature this stock only because we are 100% convinced of its enormous upside potential to deliver outsized gains to your portfolio – possibly up to 10 times your investment in the longer-term.
All the stars are lining up to make UbiquiTECH Software Corp. (OTC: UBQU) and its subsidiary company HempLife Today, a game-changer in the industry and a profit-making machine for astute investors.
But, before delving further into the explosive potential of UBQU, let’s look at what stocks in this sector have been doing in the last 6 months:
Cannabis Stocks Have Delivered MASSIVE gains.
Cannabis stocks have literally been on fire in the last 6 months, on the back of the legalization of marijuana in Massachusetts, Maine, California, and Nevada. This is in addition to the legalization of medical marijuana in North Dakota, Arkansas, and Florida.
UBQU is perfectly positioned to profit from the boom in CBD oil consumption. And, CBD Oil is an exploding market.
UBQU is already operating through the HempLifeToday.com website, offering a range of brands including the flagship CannazALL™, a high-purity Cannabidiol (CBD) based oil.
Scientific research has shown CBD to be incredibly powerful and health-enhancing, with significant analgesic, anti-cancer, anti-inflammatory, and anti-anxiety properties. All UBQU products are free from GMOs and sourced from the USA’s best growers.
The company’s other products include CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid, covering the entire gamut of niches from nutritional use to pharmaceutical use.
Sales & Earnings – Rocketing Upwards
UBQU continues to post excellent sales and earnings numbers. Revenues for 2016 grew to $3.49 MLN, its highest on record. The company anticipates that revenues for the year ending November 30, 2017 will increase over 55% to approximately $5,450,000. Earnings rocketed to $0.33 MLN in 2016 up from $0.04 MLN in 2015, a staggering increase of 840%. These are exceptionally good numbers for a company that is just getting started.
According to CEO Jim Ballas:
“The company was able to reduce its debt during the quarter with a portion of that paid through cash flow from operations and the company successfully added approximately 10,000 new customers during the year…the company finished the year with a comfortable cash flow and with a strong inventory position as well, so we’re very pleased with our growth.”
The company expects to reach 36,000 customers through its HempLifeToday e-commerce platform in 2017, up from 10,000 in 2016, for an increase of 260%.
Q1 2017 sales and earnings again wowed investors with large gains. Revenues for the quarter increased to $1,103,766 from $697,640 (+58.2%) in Q1 2016, while earnings jumped from $34,350 to $113,929 – an impressive +232%.
New Products in 2017 – More Profits in the Pipeline
UBQU announced on March 1st its newest CannazALL™ product called “Honey”, replacing the previous CannazALL™ wax “Crumble” and “Shatter”.
“Honey” not only has higher concentrations of CBD than its predecessors but also lasts longer and contains more beneficial hemp plant ingredients. In other words, a better price-to-value proposition for customers. Company COO Luke Dreyer summed up the potential of the new CannazALL™ at the Q4 2016 Earnings Conference Call:
Company COO Luke Dreyer summed up the potential of the new CannazALL™ at the Q4 2016 Earnings Conference Call:
“Our new CannazALL™ Honey is a superior product to our Crumble. It is stronger, delivers more CBD and beneficial plant materials, and is easier to use. Development of this product is also easier for the company giving us a product we can offer for a longer period of time.”
The new CannazALL™ went on sale on March 3rd and the company expects demand to be very strong, which will be fully reflected in Q2 2017 results. UBQU will also introduce new tincture and concentrated oil products during the year, increasing the concentration of CBD to boost their positive health effects.
A name change that could make you a FORTUNE
UBQU’s name involves software and does not immediately relate to Healthcare or CBD. To improve the brand’s positioning and recognition, the company’s board has decided to rename the company in order to better reflect its position as a leader in this emerging healthcare marketplace. This will leverage the brand in the USA and globally, where the company sees great potential growth.
When this happens, a flood of money could be chasing UBQU shares as more investors realize this is a legitimate and rapidly growing health and wellness play.
UBQU – Investment Opportunity of the Year
UBQU is the most exciting play in the sector but it is not the only one. The estimated size of the industry reached $7.1 BLN in 2016, a blistering 25% higher than in 2015. By 2020, legal market sales are expected to surpass $22 BLN, a stunning 200% increase from today.
However, in our opinion, UBQU is the most convincingly undervalued and potentially explosive of all the CBD stock plays. Not only does it provide premium quality products loved by its customers, but its management team has the know-how to deliver expanding sales results over and over.
Brand loyalty is high, with 25% of revenues in 2016 coming from recurring customers. Moreover, the company has launched a new referral program (HLT Referrals) in November 2016 that could increase referral conversion by up to 50% this year.
The sector’s strength is the wind in the sails of UBQU and the catalyst that could make it into an industry giant. In 2015, only 2% of Americans were aware of CBD and its extraordinary health benefits. This number reached 5% in 2016 and in the words of CEO Jim Ballas:
“When this hits critical mass then 15%, 20%, 25% of the American population is aware of CBD products, our sales – the sky is the limit of what our sales can be”.
Furthermore, the public’s attitude towards continued legalization is increasingly positive, with 60% Americans in favor compared to only 32% in 2006. The legislative panorama seems to be moving in the same direction. Delaware, Rhode Island, Kentucky, New Mexico and Vermont expect some form of legalization in 2017.
The Time To Act Is Now
During our research on the burgeoning Natural Cannabis Medication and Supplement division of the Healthcare Industry, UBQU quickly rose to the top with its focus on pain relief and the rapidly growing CBD market segment.
Our recommendation is that you secure your early position in Ubiquitech Software Corp. (OTC: UBQU) right now. Imagine what continued double and triple digit revenue and earnings growth would mean for UBQU. Life-changing gains are possible.
Do your own research on UBQU and we are sure you will also find it a unique opportunity with enormous upside. Do not wait, early investors typically experience the largest gains.
This Market Is Exploding and UBQU Is Poised for Significant Growth.
Last Paragraph Interesting
Pedanios GmbH, over the last 90 days, has achieved cash flow positive operations, with gross revenues of about C$1.15 million, which will benefit Aurora Cannabis Inc. (CVE:ACB)
SmallCapPower | May 26, 2017: Aurora Cannabis Inc. (TSXV: ACB) announced just before Friday’s closing bell that it plans to acquire Germany’s Pedanios GmbH, a wholesale importer, exporter, and distributor of medical cannabis in the European Union (EU). Aurora Cannabis’ stock had been halted for more than 24 hours pending this news.
Related:
For Aurora Cannabis, the cost of this acquisition will be approximately 3,421,756 common shares of Aurora, priced at $2.14 per share, to holders of Class B securities of Pedanios. As well, a total consideration of approximately $13,565,000 in cash and common shares is payable to the holders of Class A common shares of Pedanios, which are held by the two founders/Managing Directors of Pedanios who will continue to run the company. The cash portion for the two founders being $3,020,000 and the share portion being 4,895,026 common shares of Aurora Cannabis, priced at $2.14 per share, of which 17% will become free trading four months after closing. Aurora’s cash balance as of May 15, 2017 was $165 million.
Win Big With Our Small Cap Picks
Your email address
GET IT NOW
Pedanios is a federally licensed medical and narcotic wholesale and GMP inspected narcotic import company, holding all relevant licenses and permits, and has been successfully importing, exporting, and distributing cannabis for medical purposes since December 2015, into and within the EU.
In January 2017, Germany’s parliament unanimously passed a new medical cannabis law, which appointed physicians as gatekeepers to access, established pharmacies as the point of sale, and introduced full insurance cost-coverage for medical cannabis patients across the country. In March 2017, when the new law came into force Pedanios’ monthly sales immediately doubled and growth continues to accelerate as Germany’s 80 million citizens begin to benefit from the improvements to patient access guaranteed by the new law.
Pedanios, over the last 90 days, has achieved cash flow positive operations, with gross revenues of about C$1.15 million, and costs of approximately C$1 million. Revenues for May, up to and including May 26, 2017, were approximately C$0.5 million, reflecting a 410% increase in the daily sales pace as compared to average for the eight months prior to the introduction of the new law, and an increase over the April and March 2017 averages of 70% and 108%, respectively.
This acquisition could be bad news for Aurora Cannabis rival Cronos Group Inc. (TSXV: MJN), whose wholly-owned licensed producer, the Peace Naturals Project Inc., developed a co-brand supply agreement with Pedanios GmbH.
Just added another 10,000 at .027...I know its small potatoes compared to some of you but trying to help Im up to 100,000
very interesting read
Hello all, Just bought 11,000 at 0.028 not nearly as large overall holdings as many of you but Im getting there with what I can afford
Nice article
Dont know how many of you saw this on Motley Fool Canada What Will Aurora Cannabis Inc. Do With $185 Million Cash in 2017?
Brian Paradza | April 21, 2017 | More on: WEED ACB
Aurora Cannabis Inc.’s (TSXV:ACB) cash position could rise to $185 million by April 26, 2017, after the conclusion of its up-sized $75 million convertible debenture offering announced on April 11 which increased the offering from $40 million announced earlier the same day.
With such a well-funded position, an unquenchable thirst to catch up with industry leader Canopy Growth Corp. (TSX:WEED), and zeal to grow past Aphria Inc., the year 2017 will be a very busy year for the Aurora management team.
The market could be in for several press releases of expansion programs from Aurora. The company is completing its 800,000-square-foot greenhouse production facility at Edmonton Airport and making operational the 40,000-square-foot facility in Quebec which was gained through the acquisition of Peloton Pharmaceuticals Inc. Some $6.6 million has already been committed to the Cann Group Limited initial public offering (IPO) in Australia.
Aurora has expressly promised that the new debenture funds would be used primarily for international expansion and growth opportunities.
Could Aurora takeover Cann Group Limited?
Aurora is hungry for international expansion. That Aurora became a cornerstone investor in Cann Group’s IPO, taking up almost half the IPO’s issued shares, snatching a 19.9% stake in Australia’s first licensed medical cannabis producer, could be a sure sign the company actually wanted more, but was limited by legalities.
Canaccord Genuity (Australia) has been handling Cann Group’s capital-raising and investment-funding activities, including the May 2017 IPO. Its sister company Canaccord Genuity Corp. is structuring Aurora’s funding deals this side too. There could be a lot more connecting Aurora to Cann Group than we may know of.
Most interesting, a few weeks before the Cann Goup IPO announcement, the two majority shareholders in Cann Group sold the majority of their shares (a controlling stake) to some private investors introduced by Canaccord Genuity who will only be named after the May 25th IPO.
Could these yet-to-be-revealed investors include Aurora itself or a related entity, like Australis Capital Inc., a U.S.-based subsidiary of Aurora which was created for international expansion? Its name already sounds Australian.
Cann Group, says in its IPO prospectus that its success is largely dependent on its new Canadian technical partner Anandia Labs Inc. Anandia has partnered with Aurora in lab testing and issuing of quality assurance certificates to Aurora products to allay consumers’ pesticide fears.
Could Aurora have made the business introductions between Cann Group and Anandia?
It’s probable.
Why would Aurora be interested in growing weed in Australia?
Reports from Australia say it is time consuming and very expensive to import marijuana into Australia, as marijuana is a heavily controlled product. Growing the product locally will significantly save a lot of money.
Cann Group is the first licensed marijuana grower on Australian soil, and investing in it could be like investing in Canopy in its infancy. However, the Australian marijuana market will not likely grow as fast and be as big as the North American one.
Aurora may be rushing to play catch-up with Canopy, which already has a 15% stake in AusCann Group Holdings Ltd. based in Australia
Technical issues with Cann Group acquisition
There are legal issues to Aurora’s assuming of control in Cann Group as Australian legislation limits a foreign entity’s unchallenged acquisition of an Australian company’s stake to a 20% threshold. Beyond this limit, some legal approvals would need be sought.
Legal processes consume a lot of time and may be limiting Aurora’s Cann Group stake to 19.9% right now.
It’s not surprising that Aurora could end up taking over the control of the company and could be raising capital to fund the new entity’s construction of growing facilities.
Aurora could announce U.S. expansion plans soon
Since its announcement of the creation of Australis Capital Inc. in April 2015, there haven’t been any updates from Aurora on its U.S. expansion program in Washington.
I am positive we will get some news on the venture a few weeks after the debenture deal closes.
According to Google, "Marijuana" has been a more popular search term in Canada lately than our very own Justin Trudeau. And, not surprisingly, marijuana stocks have been the most popular topic for Motley Fool Canada readers for some time...and for good reason! However, not all "pot stocks" are created equal. That's why we've created our premium report "Motley Fool Canada: 3 Marijuana Stock Tips for Investors Today." Discover how you can gain access to which 3 stocks we believe investors should focus on in this premium Stock Advisor Canada report by clicking here now!
Fool contributor Brian Paradza has no position in any stocks mentioned.
Hi everyone, have been following this board for a month or so. Got in today not anywhere near as large a position as many of you, but nonetheless large for me. I'm hopeful after the good financials released and the upcoming press release next including a name change because the Cannabis sector is getting alot of notice we can begin to see a slow steady increase in our base! Thank you for all the informative posts